Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / MLNT - Melinta Therapeutics: sNDA Acceptance Triggers 200% Gain


MLNT - Melinta Therapeutics: sNDA Acceptance Triggers 200% Gain

On June 19th, 2019 Melinta Therapeutics (MLNT) announced the FDA accepted its BAXDELA sNDA for priority review. This sNDA would expand BAXDELA's label to include adult patients with community-acquired bacterial pneumonia (CABP). The FDA gave BAXDELA a 6-month review cycle and a PDUFA date of October 24th. Melinta traded up over 200% on June 19th after the company press release, which caught me a bit off guard. Typically, when a stock rises this much, it is due to a potential buyout or a pump dump. It took to the

Read more ...

Stock Information

Company Name: Melinta Therapeutics Inc - Ordinary Shares
Stock Symbol: MLNT
Market: NASDAQ
Website: melinta.com

Menu

MLNT MLNT Quote MLNT Short MLNT News MLNT Articles MLNT Message Board
Get MLNT Alerts

News, Short Squeeze, Breakout and More Instantly...